Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Characterizing cutaneous toxicity from doxorubicin.

Nazila Shafagati, Cole Harris Sterling, Sima Rozati et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19084

e19084 Background: While pegylated liposomal doxorubicin (PLD) is associated with reduced cardiac toxicity and improved efficacy in cutaneous malignancies...

Incidence and outcome of pulmonary hypertension in myelofibrosis.

Alexis Behne Sharma, Elicia Wang, Sruthi Selvakumar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24001

e24001 Background: Myelofibrosis (MF) is a myeloproliferative neoplasm associated with an increased risk of cardiovascular...

Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer.

Julia Ah-Reum An, Jeff Jasper, Luc Cabel et al. Jun 01, 2025 pp. 1073-1073 10.1200/jco.2025.43.16_suppl.1073

1073 Background: The combination of CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment for patients with hormone r...

Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs).

Praful Ravi, Lucia Kwak, Wanling Xie et al. Jun 01, 2025 pp. 5013-5013 10.1200/jco.2025.43.16_suppl.5013

5013 Background: There is no established role for the use of docetaxel with ADT and RT for HRLPC, with mixed results seen in prior RCTs. Prior work from I...

Association of neurocognitive impairment and financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

Daniel J. Zheng, Shalini Bhatia, Sedigheh Mirzaei et al. Jun 01, 2025 pp. 10055-10055 10.1200/jco.2025.43.16_suppl.10055

10055 Background: Adult survivors of childhood cancer are at high risk for financial hardship due to the cumulative lifetime costs of cancer-directed ther...

Landscape of homologous recombination repair pathway germline NGS gene variants in a TNBC-rich cohort of Indian breast carcinoma patients.

Amit Roychowdhury, Ghanashyam Biswas, Birendranath Banerjee Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22601

e22601 Background: According to the recent 2022-2024 published data from the GLOBOCAN, India alone contributed 15.5% of these cases with a staggering 26%...

Exploring the fibronectin/p21 (CDKN1A) functional axis in breast cancer as a marker of an aggressive disease subgroup.

Chaido Sirinian, Maria-Ioanna Argentou, Stavros Peroukidis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12557

e12557 Background: Breast cancer is a highly heterogeneous disease concerning both cancer cells and the tumor microenvironment (TME). Fibronectin (...

Racial, geographical, and socioeconomic disparities in patients with rare tumors: SEER database analysis.

Salman Khan, Aizaz Ali, Ekrem Yetiskul et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23076

e23076 Background: Socioeconomic disparities are recognized as significant contributors to variations in healthcare outcomes, influencing access to treatm...

Final results of afatinib plus chemotherapy with genomic profiling in osimertinib-refractory EGFR-mutant NSCLC: NEJ025B.

Akihiko Miyanaga, Hiromi Nagashima, Yu Utsumi et al. Jun 01, 2025 pp. 8596-8596 10.1200/jco.2025.43.16_suppl.8596

8596 Background: Osimertinib is commonly used as a first-line treatment for EGFR-mutated advanced NSCLC. However, the optimal treatment following osimerti...

Transcriptomic analysis of HER2 expression in metastatic breast cancer: Insights from a UAE patient cohort.

Rachel Su Jen Wong, Jingming Chew, Eunice Teo et al. Jun 01, 2025 pp. 1024-1024 10.1200/jco.2025.43.16_suppl.1024

1024 Background: HER2-low metastatic breast cancer (mBC) has emerged as a clinically significant subgroup since approval of trastuzumab deruxtecan. Howeve...

Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis.

Nizar J. Bahlis, Saad Z. Usmani, Thierry Facon et al. Jun 01, 2025 pp. 7529-7529 10.1200/jco.2025.43.16_suppl.7529

7529 Background: In CEPHEUS, DVRd significantly improved overall MRD negativity (MRD neg + ≥CR) and sustained MRD neg rates and PFS in patients (pts) with...

Relationship between access to shelter arrangement and adherence to breast, cervical, and colorectal cancer screening in the Providence's unhoused population.

Boris Martinez, Pamela Jennings, Matthew Strick et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13771

e13771 Background: Unhoused individuals have higher cancer death rates and reduced cancer screening. In Rhode Island, the number of unhoused individuals i...

Health-related quality of life and financial toxicity among patients with gynecological cancers in southern Nigeria: A multicenter cross-sectional study.

Chibuzor Franklin Ogamba, Adedayo Joseph, Ayodeji Adefemi et al. Jun 01, 2025 pp. 11102-11102 10.1200/jco.2025.43.16_suppl.11102

11102 Background: Gynecological cancer-related morbidity and the financial burden of care impact the quality of life of patients. However, the health-rela...

Insights into HPV mediated oropharyngeal squamous cell carcinoma: A northern Nevada epidemiological study.

Steven Cho, Samantha Chang, Sydney Althoff et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22565

e22565 Background: Human papillomavirus (HPV) is a known risk factor for oropharyngeal squamous cell carcinoma (OPSCC), with up to 90% of OPSCC cases bein...

Comprehensive analysis of NSAIDs use and oncological outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Yanlin Li, Xiaohui Jia, Mengjie Liu et al. Jun 01, 2025 pp. 2530-2530 10.1200/jco.2025.43.16_suppl.2530

2530 Background: The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on immune checkpoint inhibitors (ICIs) efficacy in non-small cell lung cance...

Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors.

Yang Zhang, Longhua Sun, Shengxiang Ren et al. Jun 01, 2025 pp. 106-106 10.1200/jco.2025.43.16_suppl.106

106 Background: MET alterations are key drivers of diverse oncogenic processes, including tumor invasion, growth, and metastasis, and are associated with...

A high-performance blood-based DNA methylation test for early detection of gastrointestinal cancers.

Xiaosheng He, Zhihua Liu, Hong Xu et al. Jun 01, 2025 pp. 3050-3050 10.1200/jco.2025.43.16_suppl.3050

3050 Background: Early detection of gastrointestinal cancers (GICs), including esophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC), r...

Safety and efficacy analysis of DNV3 plus toripalimab and chemotherapy in advanced melanoma: An open-label investigator-initiated trial.

Jing Lin, Lizhu Chen, Zuoxiang Xiao et al. Jun 01, 2025 pp. 9529-9529 10.1200/jco.2025.43.16_suppl.9529

9529 Background: Previous studies have shown that combining LAG-3 and PD-1 inhibitors is effective in advanced melanoma. Here, we presented the safety and...

Analysis of the implementation model of the organized screening strategy using the pCR DNA molecular test as the primary test for detecting high-risk human papillomavirus (HPV) for the control and elimination of cervical cancer: Pilot project for nationalization in Brazil.

Jurema Telles O Lima, Leticia Telles Sales, Caio Arruda et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13536

e13536 Background: Cervical cancer (CC) is a disease with high incidence and disproportionate mortality in low-income and socially vulnerable regions. In...

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from breast cancer.

Shipra Gandhi, Peter A. J. Forsyth, Mateusz Opyrchal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2088

TPS2088 Background: Brain metastases develop in up to 50% of patients (pts) with metastatic breast cancer. Overexpression of HER3 in brain metastatic brea...

Vault proteins as prognostic biomarkers and therapeutic targets in lower-grade gliomas.

Sebawe Syaj, Jaber H. Jaradat, Jehad A. Yassin et al. Jun 01, 2025 pp. 2082-2082 10.1200/jco.2025.43.16_suppl.2082

2082 Background: Vault proteins, including MVP, VPARP, and TEP1, are components of the vault complex, and are involved in drug resistance, DNA repair, and...

Pan-tumor application of trastuzumab deruxtecan (T-DXd) monotherapy in HER2 3+ advanced solid tumors: A pilot study challenging existing treatment restrictions.

Guanghua Rong, Bing Guo, Zhifang Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15012

e15012 Background: T-DXd, a novel HER2-targeting antibody–drug conjugate, has demonstrated potent antitumor activity in HER2+ malignancies. Although FDA h...

A predictive model for survival outcome of patients with early-stage medullary breast carcinoma: A population-based study.

Yujing Tan, Xinzhu Tian, Jiani Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13178

e13178 Background: Medullary breast carcinoma (MedBC) is a rare subtype of breast cancer, with a great number of MedBC patients diagnosed with triple-nega...

PSA as a predictor of small cell transformation in prostatic adenocarcinoma: A SEER 2000-2021 study.

David Peace, Syed Mahdee Haque, Nick Nelson Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17006

e17006 Background: Prostate cancer is the most commonly diagnosed cancer in men, affecting 1 in 8 men in the United States in their lifetime. Adenocarcino...

Risk factors for immune checkpoint inhibitor–related adverse events in the geriatric lung cancer population.

Shannon Carrigan, Maryann Aririguzo, Mark deBettencourt et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20579

e20579 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the management of lung cancer, especially for the elderly, who may prefer avoid...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page